Prostate Cancer Program

前列腺癌计划

• 批准号: 10712677
• 负责人: ERIC J SMALL
• 金额: $ 18.32万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-08-05 至 2028-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10712677
• 关键词: Address; Back; Basic Science; Biological; Biological Markers; Cancer Center Support Grant; Cancer Patient; Catchment Area; Characteristics; Clinical; Disease; Disease Management; Disease Progression; Disparity; Early Diagnosis; Foundations; Goals; Intervention; Knowledge; Malignant neoplasm of prostate; Mission; Modeling; Molecular; Morbidity - disease rate; Outcome; Patients; Population; Population Sciences; Prognostic Marker; Research; Residual Neoplasm; Risk; Science; Testing; Therapeutic; Therapeutic Intervention; Training and Education; Translational Research; Translations; Tumor Biology; advanced disease; biomarker development; biomarker validation; clinical application; clinical heterogeneity; clinical translation; community engagement; effective therapy; high risk; imaging approach; improved outcome; men; model development; mortality; novel therapeutics; outcome prediction; overtreatment; predictive marker; prognostic model; programs; targeted treatment; tumor

Prostate Cancer Program: Summary/Abstract The overarching scientific goal of the HDFCCC Prostate Cancer (PR) Program is to use a team approach to advance the understanding of tumor biology and drive translation into more effective and targeted treatment. This is done through translational research spanning discovery bench science to clinical application and back. The PR Program also seeks to specifically address the burden of prostate cancer and disparities in outcomes among patients within the catchment area. The result will be a reduction the morbidity and mortality associated with prostate cancer and its treatments by leveraging a deep understanding of the disease at the biologic, clinical, and population levels. The PR Program approaches this mission with transdisciplinary research that is richly collaborative and translational, organized around three specific aims: (1) to discover molecular features and drivers of prostate cancer; (2) to develop and validate biomarkers and models to predict outcomes in men with prostate cancer; and (3) to develop clinical interventions to improve outcomes for men with prostate cancer.

前列腺癌计划：总结/摘要 HDFCCC 前列腺癌 (PR) 计划的总体科学目标是采用团队方法 增进对肿瘤生物学的理解并推动转化为更有效和更有针对性的治疗。 这是通过从发现基础科学到临床应用并返回的转化研究来完成的。 PR 计划还旨在专门解决前列腺癌的负担和结果差异 服务范围内的患者。结果将减少相关的发病率和死亡率 通过利用对生物学疾病的深入了解，研究前列腺癌及其治疗方法， 临床和人群水平。公关计划通过跨学科研究来实现这一使命 丰富的协作和转化，围绕三个具体目标组织：（1）发现分子特征 和前列腺癌的驱动因素； (2) 开发和验证预测男性结果的生物标志物和模型 患有前列腺癌； (3) 制定临床干预措施以改善前列腺男性患者的治疗结果 癌症。